Lenvatinib is a multi-kinase inhibitor belonging to the tyrosine kinase inhibitor class, used therapeutically to treat various malignancies including thyroid cancer, hepatocellular carcinoma, renal cell… Read more


























Lenvatinib is a multi-kinase inhibitor belonging to the tyrosine kinase inhibitor class, used therapeutically to treat various malignancies including thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and advanced endometrial carcinoma. By targeting receptors such as VEGFR, FGFR, PDGFR, RET, and KIT, the drug prevents tumor angiogenesis and cellular proliferation. The research and analytical community requires high-quality materials to support the rigorous quality control of this active pharmaceutical ingredient. This catalogue provides a comprehensive range of reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled versions of the drug. These compounds are essential for accurate impurity profiling, supporting the development and validation of analytical methods, and ensuring the consistent quality of pharmaceutical products in compliance with international regulatory guidelines for drug safety and efficacy.